Curriculum Vitae Michalis (Michael) V. Karamouzis - MyLoyalCard

Name: Michalis (Michael) Karamouzis
Date of Birth: 31.01.1972
Nationality: Greek
Curriculum Vitae
Michalis (Michael) V. Karamouzis
Mail Address: Marasli 3, 10676 Kolonaki, Athens, Greece
Tel: +302130158287
Mobile: +306944290909
Fax: +302130158287
E-Mail: karam@otenet.gr
Present Working Position: Assistant Professor, Medical School, University of
Athens, Athens, Greece
Under-graduate Studies: School of Medicine, University of Patras, Patras, Greece
(1990-1995).
Post-graduate Studies:
(1) Master of Science in Pharmacokinetics and Toxicology in School of Medicine,
University of Patras, Patras, Greece.
(2) PhD in School of Medicine, University of Patras, Patras, Greece – Thesis: “Cross-
talk of retinoid receptors and the transcription factor AP-1 in laryngeal
carcinogenesis and possible applications in chemoprevention”.
Previous working positions:
1) Fellow of Internal Medicine, Department of Internal Medicine, 251 Hospital of
Greek Air Force, Athens, Greece (4\9\98-4\7\99).
2) Fellow of Internal Medicine, Department of Internal Medicine, University
Hospital of Patras, Patras, Greece (12\7\99-25\3\01).
3) Fellow of Hematology-Oncology, Division of Hematology-Onvology, Department
of Medicine, University Hospital of Patras, Patras, Greece (29\6\01-15\1\02).
1
1

4) Fellow of Medical Oncology, St. Savvas Anticancer-Oncological Hospital,
Athens, Greece (24/3/2003-24/3/2006).
5) Visiting Assistant Professor, Division of Hematology-Oncology, Department of
Medicine, University of Pittsburgh, USA (01/09/2006-31/08/2007).
Publications in peer-reviewed journals
1) S. Andrikopoulos, M. Karamouzis, G. Papachristou, A. Vagenakis & H
Kalofonos: "The status of undergraduate oncology education in Medical Schools
in Greece and abroad", J Cancer Educ, 14(4): 223-227, 1999.
2) H.P. Kalofonos, M.V. Karamouzis & A.A. Epenetos: "Radioimmunoscintigraphy
in patients with ovarian cancer", Acta Oncol, 40(5): 549-557, 2001.
3) S. Voulgaris, M. Partheni, M. Karamouzis, P. Dimopoulos, N. Papadakis & H.P.
Kalofonos: "Intratumoral doxorubicin in patients with malignant brain gliomas",
Am J Clin Oncol, 25(1): 60-64, 2002.
4) A.G. Papatsoris, F.A. Mpadra & M.V. Karamouzis: "Prostatic adenocarcinoma
presenting as solitary cerebellar metastasis. Case report and review of the
literature", Tumori, 88(1): 61-64, 2002.
5) M.V. Karamouzis, T. Papadas, I. Varakis, G. Sotiropoulou-Bonikou & A.G.
Papavassiliou: "Induction of the CBP transcriptional co-activator early during
laryngeal carcinogenesis", J Cancer Res Clin Oncol, 128(3): 135-140, 2002.
6) T. Papadas, N. Charokopos, M.V. Karamouzis, C. Pierakeas, M. Symeonidi, G.
Economou & P. Goumas: "Rehabilitation after laryngectomy - A practical
approach and guidelines", J Cancer Educ, 17(1): 37-39, 2002.
7) M.V. Karamouzis, VG Gorgoulis, A.G. Papavassiliou: "Transcription factors and
neoplasia: vistas in novel drug design", Clin Cancer Res, 8(6): 949-961, 2002.
8) M.V. Karamouzis, E. Likaki-Karatza, F.A. Mpadra, P. Ravazoula, D. Koukouras,
E. Tzorakoeleptherakis, A.G. Papavassiliou & H.P. Kalofonos: "Non-palpable
breast carcinomas: correlation of mammographically detected malignant-
appearing microcalcifications and molecular prognostic factors", Int J Cancer,
102(1): 86-90, 2002.
9) E. Likaki-Karatza, F.A. Mpadra, M.V. Karamouzis, P. Ravazoula, D. Koukouras,
S. Margariti & I. Dimopoulos: "Acute lymphoblastic leukemia (ALL) relapse in
2
2

east diagnosed with gray-level and color doppler ultrasonography", J Clin Ultr,
30(9): 552-556, 2002.
10) A.G. Papatsoris, F.A. Mpadra, M.V. Karamouzis & C.Y. Frangides: "Bruccelar
orcheoepididimytis in Western Greece: ten years experience", Int J Infect Dis,
6(4): 309-313, 2002.
11) A.G. Papatsoris, F.A. Badra & M.V. Karamouzis: "Post-traumatic testicular
torsion". Ulus Trauma Derg, 9(1): 70-71, 2003.
12) E.G. Solomou, G. Patriarheas, F.A. Mpadra, M.V. Karamouzis & I. Dimopoulos:
"Asymptomatic adult cystic lymphangioma of the spleen: Case report and review
of the literature". Magn Reson Imaging, 21: 81-84, 2003.
13) A.G. Papatsoris, F.A. Badra, M.V. Karamouzis, E. Likaki-Karatza & T. Karatzas:
"Torsion of undescended testis in an adult with Down's syndrome". Int J Urology,
10: 233-235, 2003.
14) M.V. Karamouzis, M. Melachrinou, M. Fratzoglou, Ch Labropoulou-Karatza &
H.P. Kalofonos: "Hepatocellular carcinoma metastasis in the pituitary gland: case
report and review of the literature", J Neuro-Oncology, 63(2): 173-177, 2003.
15) M.V. Karamouzis, F.A. Badra & A.G. Papatsoris: "A case of colonic ischemia
mimicking carcinoma". Int J Gastrointestinal Cancer, 32(2-3): 165-168, 2003.
16) M.V. Karamouzis, G. Sotiropoulou-Bonikou, G. Vandoros, I. Varakis & A.G.
Papavassiliou: “Retinoid-X-receptor alpha (RXRα) expression during laryngeal
carcinogenesis: Detrimental or beneficial event?”. Cancer Lett, 199(2): 175-183,
2003.
17) Α. Alexopoulos, D. Tryfonopoulos, M.V. Karamouzis, G. Gerasimidis, I. Karydas,
K. Kandilis, J. Stavrakakis, H. Stavrinides, C. Georganta, A. Ardavanis & G.
Rigatos: “Evidence for In Vivo Synergism between Docetaxel and Gemcitabine in
Patients with Metastatic Breast Cancer”. Ann Oncol, 15: 88-94, 2004.
18) M.V. Karamouzis, G. Sotiropoulou-Bonikou, G. Vandoros, I. Varakis & A.G.
Papavassiliou: “Differential expression of retinoic acid receptor beta (RARβ) and
AP-1 transcription factor in normal, premalignant and malignant human laryngeal
tissues”. Eur J Cancer, 40: 761-773, 2004.
19) M.V Karamouzis & A.G. Papavassiliou: “COX-2 inhibition in cancer
therapeutics: a field of controversy or a magic bullet?”. Expert Opin Invest Drugs,
13: 359-372, 2004.
3
3

20) Α. Alexopoulos, M.V. Karamouzis, H. Stavrinides, A. Ardavanis, K. Kandilis,
J. Stavrakakis, C. Georganta & G. Rigatos: “Phase II study of pegylated liposomal
doxorubicin (Caelyx ® ) and docetaxel as first line treatment in metastatic breast
cancer” Ann Oncol, 15: 891-895, 2004.
21) H.P. Kalofonos, D. Bafaloukos, T.G. Kourelis, M.V. Karamouzis, P. Megas, G.
Iconomou, D. Dimitropoulos, P. Kosmidis & E. Lampiris: "Adriamycin and cis-
platinum as first line treatment in unresectable locally advanced or metastatic adult
soft tissue sarcomas". Am J Clin Oncol, 27: 307-311, 2004.
22) Α. Alexopoulos, M.V. Karamouzis & G. Rigatos: “In Vivo Synergism
between Docetaxel and Gemcitabine in Patients with Metastatic Breast Cancer:
The general concept and the future perspectives of such a rationale approach”,
Semin Oncol, 31 (suppl 5): 25-30, 2004.
23) A.G. Papatsoris, A. Triantafyllidis, A. Gekas, M.V. Karamouzis & T. Rosenbaum:
“Leydig cell tumor of the testis. New cases and review of the current literature”.
Tumori, 90: 422-423, 2004.
24) M.V. Karamouzis, N. Apostolikas, Ch. Georganta, G. Lainakis, K. Kandylis & G.
Rigatos: “A case of relapsed CD20 (+) mixed cellularity Hodgkin‟s Disease
treated with sequential Rituximab and Radiotherapy” Am J Haematol, 77: 418-
419, 2004.
25) F.A. Badra, M.V. Karamouzis, V. Zolota & V. Pastromas: “A case of multi-organ
Langerhan‟s cell histiocytosis presented with pneumothorax”, Eur J Intern Med,
15: 467-469, 2004.
26) M.V. Karamouzis: “The status of chemoprevention in the current cancer
therapeutic armamentarium”, Journal of BUON, 9: 363-372, 2004.
27) H.P. Kalofonos, C. Kourousis, M.V. Karamouzis, G. Iconomou, P. Megas & V.
Georgoulias: “A phase II study of docetaxel and epirubicin in advanced adult soft
tissue sarcomas”, Sarcoma, 4: 129-133, 2004.
28) M.V. Karamouzis & A.G. Papavassiliou: “Retinoid receptors cross talk in
respiratory epithelium cancer chemoprevention”, Trends in Molecular Medicine,
11: 10-16, 2005.
29) A.G. Papatsoris, M.V. Karamouzis & A.G. Papavassiliou: “Novel insights into the
implication of the IGF-1 network in prostate cancer”, Trends in Molecular
Medicine, 11: 52-55, 2005.
4
4

30) Α.G. Papatsoris, M.V. Karamouzis & A.G. Papavassiliou: “Novel biological
agents for the treatment of hormone-refractory prostate cancer”, Curr Med Chem,
12(3): 277-296, 2005.
31) M.V. Karamouzis, A. Ardavanis, A. Alexopoulos, A. Papadopoulou, N.
Apostolikas & G. Rigatos: “Multiple cutaneous acral metastases in a female with
breast adenocarcinoma treated with pegylated liposomal doxorubicin: Incidental or
etiological association?”, Eur J Cancer Care, 14: 267-271, 2005.
32) A. Ardavanis, D. Tryfonopoulos, G. Orfanos, M. Karamouzis, A. Scorilas, A.
Alexopoulos & G. Rigatos: “Safety and Efficacy of Trastuzumab Every 3 Weeks
Combined with Cytotoxic Chemotherapy in Patients with HER2-Positive
Recurrent Breast Cancer: Findings from a Case Series”. Onkologie, 28(11):558-
564, 2005.
33) A. Ardavanis, D. Tryfonopoulos, G. Orphanos, G. Ioannidis, M. Karamouzis & G.
Rigatos: “First-line chemotherapy with fluorouracil-epirubicin-navelbine (FEN)
combination in advanced breast cancer”. Anticancer Res, 25: 4493-4498, 2005.
34) A. Ardavanis, M.V. Karamouzis, A. Alexopoulos & G. Rigatos: “Simultaneous
endometrioid ovarian and uterine carcinoma diagnosed after in-vitro fertilization
procedure – case report and review of the literature”, Eur J Gynaecol Oncol, 26:
654-656, 2005.
35) G. Vandoros, P.A. Konstantinopoulos, G. Sotiropoulou-Bonikou, A. Kominea, P.
Andrikopoulos, G.I. Papachristou, M.V. Karamouzis, M. Gkermpesi, I. Varakis, &
A.G. Papavassiliou: “PPAR-gamma is expressed and NF-KB pathway is activated
and correlates positively with COX-2 expression in stromal myofibroblasts
surrounding colon adenocarcinomas. J Cancer Res Clin Oncol, 132: 76-84, 2006.
36) F.A Badra, M.V. Karamouzis, E. Likaki-Karatza, P. Ravazoula, E.
Tzorakoelepftherakis, D. Koukouras, G. Iconomou, D. Siablis, A.G. Papavassiliou
& H.P. Kalofonos: “Non-palpable breast carcinomas: correlation of
mammographically detected malignant-appearing microcalcifications and
epidermal growth factor receptor (EGFR) family expression, Cancer Lett, 244: 34-
41, 2006.
37) Μ.V. Karamouzis, A.A. Ifanti, G. Iconomou, A.G. Vagenakis & H.P. Kalofonos:
“Medical students‟ views of undergraduate oncology education: A comparative
study”, Educ Health (Abingdon), 19: 61-70, 2006.
5
5

38) M.V. Karamouzis, P. Liodantonaki & G. Rigatos: “A case of breast carcinoma late
metastasis to the kidney”, Am J Clin Oncol, 29:209-210, 2006.
39) A. Ardavanis, A. Scorilas, D. Tryfonopoulos, G. Orphanos, I. Missitzis, M.V.
Karamouzis, M. Chrysochoou, A. Sotiropoulou, N. Arnogiannaki, G. Ioannidis, G.
Pissakas, G. Rigatos: “Multidisciplinary Therapy of Locally Far-Advanced or
Inflammatory Breast Cancer with Fixed Perioperative Sequence of Epirubicin,
Navelbine, and Fluorouracil Chemotherapy, Surgery, and Radiotherapy: Long-
Term Results”, The Oncologist, 11: 563-573, 2006.
40) M.V. Karamouzis & A.G. Papavassiliou: “The IGF-1 network in lung carcinoma
therapeutics”, Trends Mol Med, 12:595-602, 2006.
41) M.V. Karamouzis, A. Fida, N. Apostolikas & G. Rigatos: “A case of HER-2 (+)
squamous cell breast carcinoma: an unusual presentation of an unusual clinical
entity”, Eur J Surg Oncol, 32:1250-1251, 2006.
42) E.G. Iliopoulou, M.V. Karamouzis, I. Missitzis, A. Ardavanis, C.N. Baxebanis, G.
Rigatos, M. Papamichail, S.A. Perez: “Increased frequency of CD4+ cells
expressing CD161 in cancer patients”, Clin Cancer Res, 12: 6901-6909, 2006.
43) M.V. Karamouzis, H. Linardou, G. Papadopoulos, E. Bousboukea, D. Kanaloupiti,
M. Bitza, N. Spourlis & D. Bafaloukos: “Gastrointestinal solitary metastases from
lung squamous cell carcinoma”, Lung Cancer, 55: 251-252, 2007.
44) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou: “The AP-1
Transcription Factor in Respiratory Epithelium Carcinogenesis”, Mol Cancer Res,
5: 109-120, 2007.
45) A.G. Papatsoris, M.V. Karamouzis & A.G. Papavassiliou: “The power and
promise of "rewiring" the mitogen-activated protein kinase network in prostate
cancer therapeutics”, Mol Cancer Ther, 6: 811-819, 2007.
46) P.A. Konstantinopoulos, R.J. Sullivan, M.V. Karamouzis, & B.J. Dezube:
“Investigational agents for treatment of AIDS-Related Kaposi Sarcoma”, Expert
Opin Investig Drugs, 16: 495-504, 2007.
47) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou: “Roles of
CREB-Binding Protein (CBP)/p300 in respiratory epithelium tumourigenesis”,
Cell Res, 17: 324-332, 2007.
48) M.V. Karamouzis, F.A. Badra & A.G. Papavassiliou: “Breast cancer: the upgraded
role of HER-3 and HER-4”, Int J Biochem Cell Biol, 39: 851-856, 2007.
6
6

49) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou: “The molecular
basis of retinoids‟ use in breast cancer chemoprevention”, Cell Oncol, 29: 183-
184, 2007.
50) P.A. Konstantinopoulos, M.V. Karamouzis & A.G. Papavassiliou: “Focus on
acetylation: of histones and beyond, from cancer and beyond”, Expert Opin
Investig Drugs, 16: 569-571, 2007.
51) M.V. Karamouzis, S.A. Perez, D.V. Skarlos, A. Ardavanis, N.N. Sotiriadou, E.G.
Iliopoulou, M.L. Salagianni, P.A. Sotiropoulou, G. Orfanos, C.N. Baxevanis, G.
Rigatos & M Papamichail: “CD4+CD25+ Regulatory T Cell frequency in
HER/neu positive and negative advanced stage breast cancer patients”, Clin
Cancer Res, 13: 2714-2721, 2007.
52) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou: “The role of
STATs in lung carcinogenesis: an emerging target for novel therapeutics”, J Mol
Med, 85: 427-436, 2007.
53) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou: “Intriguing
issues of EGFR targeting in head and neck cancer”, Ann Oncol, 18: 962, 2007.
54) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou: “Epigenetics in
respiratory epithelium carcinogenesis: prevention and therapeutic challenges”,
Cancer Treat Rev, 33: 284-288, 2007.
55) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou:
“Compartmentalization of EGFR signalling might potentiate the optimal use of
EGFR inhibitors in cancer therapeutics”, Br J Cancer, 96: 1924-1925, 2007.
56) P.A. Konstantinopoulos, M.V. Karamouzis & A.G. Papavassiliou: “Targeting
post-translational modifications and functional regulation of the Ras superfamily
of small G-proteins for anticancer drug development”, Nat Rev Drugs Discov,
6:541-555, 2007.
57) M.V. Karamouzis, J.R. Grandis & A. Argiris: “Therapies against epidermal
growth factor receptor in aerodigestive carcinomas”. JAMA, 298: 70-82, 2007.
58) P.A. Konstantinopoulos, M.V. Karamouzis & A.G. Papavassiliou: “Selective
modulation of the erythropoietic and tissue-protective effects of erythropoietin:
time to reach the full therapeutic potential of erythropoietin”, BBA – Reviews on
Cancer, 1776: 1-9, 2007.
7
7

59) M.V. Karamouzis, G. Ioannidis & G. Rigatos: “Quality of life in metastatic breast
cancer patients under chemotherapy or supportive care: a single-institution
comparative study”, Eur J Cancer Care, 16: 433-438, 2007.
60) A. Argiris, S. Agarwala, M.V. Karamouzis, L.A. Burmeister & S.E. Carty: “A
phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary
thyroid cancer, Invest New Drugs, 2007.
61) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou: “Trastuzumab
– Mechanism of action and use in clinical practice”, New Engl J Med, 357: 1664,
2007.
62) M.V. Karamouzis & A. Argiris: “Update on the role of EGFR inhibitors in cancer
therapeutics”, Cancer Treat Res, 135: 257-275, 2007.
63) P.A. Konstantinopoulos, G.P. Vandoros, M.V. Karamouzis, M. Gkermpesi, G.
Sotiropoulou-Bonikou & A.G. Papavassiliou: “EGF-R is expressed and AP-1 and
NF-KB are activated in stromal myofibroblasts surrounding colon
adenocarcinomas paralleling expression of cyclooxygenase-2 and VEGF”, Cell
Oncol, 29: 477-482, 2007.
64) M.V. Karamouzis, A. Argiris & J.R. Grandis: “Clinical applications of gene
therapy in head and neck cancer”, Curr Gene Ther, 7: 446-457, 2007.
65) P.A. Konstantinopoulos, M.V. Karamouzis, A.G. Papatsoris & A.G.
Papavassiliou: “Matrix metalloproteinase inhibitors as anticancer agents”, Int J
Biochem Cell Biol, 40: 1156-1168, 2007.
66) A. Argiris, M.V. Karamouzis, J. Johnson, D.E. Heron, D. Eibling, E. Cano, S.
Urba, J, Gluckman Y. Wang & S. Agarwala: “A phase III randomized trial of
postoperative radiotherapy with or without carboplatin in patients with high risk,
locally advanced squamous cell carcinoma of the head and neck”, Laryngoscope,
118: 444-449, 2007.
67) M.V. Karamouzis, P.A. Konstantinopoulos, F.A. Badra & A.G. Papavassiliou:
“SUMO and estrogen eceptors in breast cancer”, Breast Cancer Res Treat, 107:
195-210, 2008.
68) P.A. Konstantinopoulos, M.V. Karamouzis & A.G. Papavassiliou:
“Thaizolidinediones and cardiovascular events: Is concomitant aspirin use a
confounder?”, JAMA, 299: 1539, 2008.
8
8

69) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou: “ErbB/HER
receptor family in breast cancer – The more we search the more we learn”, Ann
Oncol, 19: 1020-1021, 2008.
70) M.V. Karamouzis, A. Argiris, D. Raben & R. Ferris: “Head and Neck Cancer”,
Lancet, 371: 1695-1709, 2008.
71) G.P. Vandoros, T. Manolidis, M.V. Karamouzis, M. Gkermpesi, M.
Lambropoulou, A.G. Papatsoris, I. Zachos & P.A. Konstantinopoulos:
“Leiomyosarcoma of the prostate: case report and review of 54 previously
published cases”. Sarcoma, 2008.
72) P.A. Konstantinopoulos, M.V. Karamouzis & A.G. Papavassiliou: “Educational
and Social-Ethical Issues in the Pursuit of Molecular Medicine”. Mol Med, 15: 60-
63, 2009.
73) Zachos I, Konstantinopoulos PA, Vandoros GP, Karamouzis MV, Papatsoris AG,
Podimatas T, Papachristodoulou A, Chrisofos M, Deliveliotis C, Papavassiliou
AG: “Predictive value of telomerase reverse transcriptase expression in patients
with high risk superficial bladder cancer treated with adjuvant BCG
immunotherapy”. J Cancer Res Clin Oncol, 135: 1169-75, 2009.
74) M.V. Karamouzis, S. Moschos: “Endostatin in cancer therapeutics”, Expert Opin
Biol Ther , 9: 641-648, 2009.
75) D.E. Heron, R.L. Ferris, M.V. Karamouzis, R.S. Andrade, E.L. Deeb, S. Burton,
W.E. Gooding, B.F. Branstetter, J.M. Mountz, J.T. Johnson, A. Argiris, J.R.
Grandis, S.Y. Lai: „Stereotactic Body Radiotherapy for Recurrent Squamous Cell
Carcinoma of the Head and Neck: Results of a Phase I Dose-Escalation Trial”. Int
J Radiat Oncol Biol Phys, 75: 1493-500, 2009.
76) M.V. Karamouzis, P.A. Konstantinopoulos, A.G. Papavassiliou: “Targeting c-Met
as a strategy to overcome cross-talk related resistance to EGFR protein -targeting
agents in cancer therapeutics”, Lancet Oncol, 10: 709-77, 2009.
77) A.G. Pallis, M.V. Karamouzis, P.A. Konstantinopoulos, A.G. Papavassiliou:
“Moleular networks in respiratory epithelium carcinomas”, Cancer Lett, 95: 1-6,
2010.
78) I. Zachos, P.A. Konstantinopoulos, V. Tzortzis, S. Gravas, A. Karatzas, M.V.
Karamouzis, M. Melekos, AG. Papavassiliou: “Systemic therapy of metastatic
9
9

ladder cancer in the molecular era: current status and future promise”, Expert
Opin Investig Drugs, 19: 875-87, 2010.
79) A. Kotsinas, I.S. Pateras, P.S. Galanos, M.V. Karamouzis, P.P. Sfikakis, V.G.
Gorgoulis: “Why is p53-inducible gene 3 rarely affected in cancer?”, Oncogene,
29: 5220, 2010.
80) E.G. Iliopoulou, P. Kountourakis, M.V. Karamouzis, D. Doufexis, A. Ardavanis,
C.N. Baxevanis, G. Rigatos,M. Papamichail, S.A. Perez: “A phase I trial of
adoptive transfer of allogeneic natural killer cells in patients with advanced non-
small cell lung cancer”, Cancer Immunol Immunother, 59: 1781-89, 2010.
81) A.G. Pallis, M.V. Karamouzis: “DNA repair pathways and their implication in
cancer treatment”, Cancer Metastasis Rev, 29: 677-85, 2010.
82) Argiris, M.V. Karamouzis, W.E. Gooding, B.F. Branstetter, S. Zhong, L.E. Raez,
P. Savvides, M. Romkes: “Phase II trial of pemetrexed and bevacizumab in
patients with recurrent or metastatic head and neck cancer”, J Clin Oncol, 29:
1140-45. 2011.
83) Argiris, M.V. Karamouzis: “Empowering induction therapy for locally advanced
head and neck cancer”, Ann Oncol, 22: 773-781, 2011.
84) Argiris, M.V. Karamouzis, R. Smith, A. Kotsakis, M.K. Gibson, S.Y. La, S. Kim,
B.F. Branstetter, Y. Shuai, M. Romkes, L. Wang, J.R. Grandis, R.L. Ferris, J.T.
Johnson & D.E. Heron: “Phase I trial of pemetrexed in combination with
cetuximab and concurrent radiotherapy in patients with head and neck cancer”,
Ann Oncol, 22: 2482-2488, 2011.
85) M.V. Karamouzis & A.G. Papavassiliou: “Transcription Factor Networks as
Targets for Therapeutic Intervention of Cancer - The Breast Cancer Paradigm”,
Mol Med 2011.
86) M.V. Karamouzis & A.G. Papavassiliou: “Targeting insulin-like growth factor in
breast cancer therapeutics”, Crit Rev Oncol Hematol, 2012, in press.
Abstracts in international congresses
1) M.V. Karamouzis, et al.: “Circulating Regulatory T Cells in Advanced Breast
Cancer Patients”, 42 th ASCO Annual Meeting, Atlanda, Giorgia, U.S.A., June 2-6,
2006.
10
10

2) E.G. Iliopoulou, M.V. Karamouzis, et al.: “Characterization of a subset of CD4+ T
cells expressing CD161 in cancer patients and healthy individuals”, 42 th ASCO
Annual Meeting, Atlanda, Giorgia, U.S.A., June 2-6, 2006.
3) M.V. Karamouzis, et al.: “Phase II trial of pemetrexed (P) and bevacizumab (B) in
patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma
(HNSCC): an interim analysis”, 43 th ASCO Annual Meeting, Chicago, Illinois,
U.S.A., June 1-5, 2007.
4) R. Smith, M.V. Karamouzis, et al.: “Phase I trial of pemetrexed (P) in
combination with cetuximab (C) and concurrent radiotherapy (RT) in patients
(pts) with head and neck cancer (HNC)”, 43 th ASCO Annual Meeting, Chicago,
Illinois, U.S.A., June 1-5, 2007.
5) J. Johnson, S. Agarwala, M.V. Karamouzis, et al.: “Phase III randomized trial of
postoperative radiotherapy (RT) with or without carboplatin (Cb) in patients (pts)
with head and neck squamous cell carcinoma (HNSCC)”, 43 th ASCO Annual
Meeting, Chicago, Illinois, U.S.A., June 1-5, 2007.
6) D.E. Heron, R.L. Ferris, S. Burton, S. Lai, M.V. Karamouzis, et al.: “Phase I dose
escalation study of fractionated stereotactic radiosurgery (fSRS) for recurrent
squamous cell carcinoma of the head and neck (SCCHN)”, 43 th ASCO Annual
Meeting, Chicago, Illinois, U.S.A., June 1-5, 2007.
7) Argiris, M.V. Karamouzis, et al.: “Phase II trial of docetaxel (T), cisplatin (P), and
cetuximab (E) followed by concurrent radiation (RT), P, and E in locally advanced
head and neck squamous cell carcinoma (HNSCC), 43 th ASCO Annual Meeting,
Chicago, Illinois, U.S.A., June 1-5, 2007.
8) M. Gibson, M.V. Karamouzis, et al.: “Phase I trial of pemetrexed in combination
with cetuximab and concurrent radiotherapy in head and neck cancer (HNC), 49 th
ASTRO Annual Meeting, Los Angeles, California, U.S.A., October 28-November
1, 2007.
9) S.C. Buch, M.V. Karamouzis, et al.: “Gene expression signatures correlate with
survival of patients with head and neck cancer treated with platinum-based
regimens”, AACR Annual Meeting, San Diego, California, U.S.A., April 12-16,
2008.
10) T. Feinstein, L. Raez, K. Rajasenan, M. Gibson, P. Savvides, M.V. Karamouzis, et
al.: “Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or
11
11

metastatic head and neck squamous cell carcinoma (HNSCC): updated results of a
phase II trial”, 44 th ASCO Annual Meeting, Chicago, Illinois, U.S.A., May 30-
June 3, 2008.
11) E. G. Iliopoulou, P. Kountourakis, M. V. Karamouzis, et al.: “A phase I trial of
adoptive transfer of allogeneic natural killer (NK) cells in patients (pts) with
advanced non-small cell lung cancer (NSCLC)”, ASCO Annual Meeting, Orlando,
Florida, U.S.A., May 29-June 2, 2009.
12) A. Argiris, M.V. Karamouzis, W.E. Gooding, B. Branstetter, S. Zhong, L.E. Raez,
P. Savvides, M. Romkes: “Pemetrexed (P) and bevacizumab (B) in patients (pts)
with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck
(SCCHN): Final results and correlation with TS, MTHFR, and VEGF gene
polymorphisms”, ASCO Annual Meeting, Chicago, Illinois, U.S.A., June, 2010.
13) M.V. Karamouzis, N. Dioufa, E. Farmaki, C. Piperi, H. Kiaris, A. Papavassiliou:
“Essential role of p53 of stromal fibroblasts (fibs) in the reciprocal interaction
between PC3 prostate cancer cells and stromal fibs”, ASCO Annual Meeting,
Chicago, Illinois, U.S.A., June, 2011.
Participation in scientific societies
1) Full ESMO Member (European Society of Medical Oncology) – Chair of ESMO-
Young Oncologists Committee (2010-2012)
2) Active ASCO Member (American Society of Clinical Oncology).
3) Associate AACR Member (American Association of Cancer Research).
Last Update: October 2012
12
12